Earnings call transcript: Manolete lifts forward book to record in H2 2026

Manolete Partners reported FY 2026 realized revenue of GBP 27.95 million, with adjusted realized PBT rising to GBP 1.9 million excluding a GBP 1.8 million bad debt provision versus GBP 800,000 a year earlier. The forward book hit a record GBP 67 million, up 37%, while gross cash receipts rose 4% to GBP 26.6 million and gross margin improved to 37% from 32%. Shares edged up 1.33% to $38, but the stock remains far below its 52-week high as investors weigh improved operating trends against debtor risk and leverage.

Analysis

The market is still pricing this like a stale value trap, but the operating inflection is more about mix than headline profit. A larger forward book matters here because the business has unusually high operating leverage: once case inventory is built, incremental conversions should drop disproportionately to profit and cash, especially if management can sustain the shift toward higher-value claims. The key second-order effect is that a stronger in-house legal bench should not just lift throughput; it should also reduce reliance on external counsel and improve settlement economics, which can compound margins faster than the market is likely modeling.

The real near-term risk is not demand for cases, but the conversion path from book value to cash. One or two debtor issues can dominate sentiment because they hit both reported earnings and the company’s ability to return capital, and that keeps the equity hostage to collections timing over the next 1-2 quarters. If recoveries slip, the bull case gets delayed even if the underlying portfolio is intact; if they come through, the stock can rerate sharply because the market is anchored to a pessimistic liquidation-style multiple rather than earnings power.

I think the consensus is missing that management is implicitly telling you the valuation gap will likely close through balance-sheet repair before buybacks ever become the catalyst. That means the cleanest upside path is not a classic multiple rerating on "growth," but a step-change in confidence once the market sees collections normalize and the forward book monetize without further provisions. In that sense, the stock is more of a self-help cash realization story than a pure earnings recovery, which creates a more binary setup over the next 6-12 months.

Key Decisions for Investors

• Long MANO for a 6-12 month self-help rerating: entry is attractive on any post-results fade; target is a re-rate toward a mid-teens earnings multiple if debtor recovery and forward-book conversion hold.
• Use call spreads rather than outright equity for MANO over the next 3-6 months to isolate upside from cash-recovery headlines while limiting downside if collections disappoint.
• Pair trade: long MANO / short a higher-multiple financial-services name with less balance-sheet optionality. The long leg is a catalyst-driven recovery story; the short leg offsets macro multiple risk.
• Add only after evidence of collections improvement in the next update. If overdue debtors fail to trend lower again, the thesis shifts from mispriced to structurally impaired.
• For event-driven accounts, buy MANO on confirmation of recovery on the two large debtors; that would be the highest-conviction catalyst for a fast sentiment reset over days to weeks.